Showing results (491-500 of 520) with videos related to
Sort By:
Pageof 52
Pharmacology & Therapeutics|September 2, 2022
Complex in vitro 3D models of digestive system tumors to advance precision medicine and drug testing: Progress, challenges, and trendsSheng-Lei Song, Bo Li, Mariana R Carvalho, et al.Cell Death & Disease|March 29, 2025
Oncogenic activation of SMYD3-SHCBP1 promotes breast cancer development and is coupled with resistance to immune therapyLihua Mo, Min Deng, Ragini Adhav, et al.Nature|May 1, 2009
Bmi1 regulates mitochondrial function and the DNA damage response pathwayJie Liu, Liu Cao, Jichun Chen, et al.Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|December 11, 2020
Enhanced Protein Damage Clearance Induces Broad Drug Resistance in Multitype of Cancers Revealed by an Evolution Drug-Resistant Model and Genome-Wide siRNA ScreeningFangyuan Shao, Xueying Lyu, Kai Miao, et al.Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|September 13, 2021
Activation of FGFR2 Signaling Suppresses BRCA1 and Drives Triple-Negative Mammary Tumorigenesis That is Sensitive to ImmunotherapyJosh Haipeng Lei, Mi-Hye Lee, Kai Miao, et al.Nature Medicine|September 28, 2011
Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155Suhwan Chang, Rui-Hong Wang, Keiko Akagi, et al.Journal for Immunotherapy of Cancer|January 29, 2026
DUSP22 dephosphorylates LGALS1 to enhance T cell-driven antitumor immunityLijian Wang, Yutong Guo, Yujie Dai, et al.Theranostics|August 6, 2026
A miniaturized-tumor culture platform for developing anti-tumor immunotherapiesYangyang Feng, Ling Li, Josh Haipeng Lei, et al.Cancer Cell|February 5, 2010
SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stressHyun-Seok Kim, Krish Patel, Kristi Muldoon-Jacobs, et al.Nature Materials|January 24, 2025
Interlayer reconstruction phase transition in van der Waals materialsJunwei Zhang, Laiyuan Wang, Jingtao Lü, et al.Pageof 52